237 related articles for article (PubMed ID: 16585555)
1. DOCK2 is required in T cell precursors for development of Valpha14 NK T cells.
Kunisaki Y; Tanaka Y; Sanui T; Inayoshi A; Noda M; Nakayama T; Harada M; Taniguchi M; Sasazuki T; Fukui Y
J Immunol; 2006 Apr; 176(8):4640-5. PubMed ID: 16585555
[TBL] [Abstract][Full Text] [Related]
2. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
3. Control of NKT cell differentiation by tissue-specific microenvironments.
Yang Y; Ueno A; Bao M; Wang Z; Im JS; Porcelli S; Yoon JW
J Immunol; 2003 Dec; 171(11):5913-20. PubMed ID: 14634102
[TBL] [Abstract][Full Text] [Related]
4. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
5. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
6. Immediate antigen-specific effector functions by TCR-transgenic CD8+ NKT cells.
Wingender G; Berg M; Jüngerkes F; Diehl L; Sullivan BA; Kronenberg M; Limmer A; Knolle PA
Eur J Immunol; 2006 Mar; 36(3):570-82. PubMed ID: 16506291
[TBL] [Abstract][Full Text] [Related]
7. Role of the complementarity-determining region 3 (CDR3) of the TCR-beta chains associated with the V alpha 14 semi-invariant TCR alpha-chain in the selection of CD4+ NK T Cells.
Ronet C; Mempel M; Thieblemont N; Lehuen A; Kourilsky P; Gachelin G
J Immunol; 2001 Feb; 166(3):1755-62. PubMed ID: 11160221
[TBL] [Abstract][Full Text] [Related]
8. Targeted expression of human CD1d in transgenic mice reveals independent roles for thymocytes and thymic APCs in positive and negative selection of Valpha14i NKT cells.
Schümann J; Pittoni P; Tonti E; Macdonald HR; Dellabona P; Casorati G
J Immunol; 2005 Dec; 175(11):7303-10. PubMed ID: 16301636
[TBL] [Abstract][Full Text] [Related]
9. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.
Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T
Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881
[TBL] [Abstract][Full Text] [Related]
10. CD1d-restricted NKT cells: an interstrain comparison.
Hammond KJ; Pellicci DG; Poulton LD; Naidenko OV; Scalzo AA; Baxter AG; Godfrey DI
J Immunol; 2001 Aug; 167(3):1164-73. PubMed ID: 11466330
[TBL] [Abstract][Full Text] [Related]
11. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
[TBL] [Abstract][Full Text] [Related]
12. The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells.
Schrantz N; Sagiv Y; Liu Y; Savage PB; Bendelac A; Teyton L
J Exp Med; 2007 Apr; 204(4):841-52. PubMed ID: 17389239
[TBL] [Abstract][Full Text] [Related]
13. A novel mouse model for invariant NKT cell study.
Wakao H; Kawamoto H; Sakata S; Inoue K; Ogura A; Wakao R; Oda A; Fujita H
J Immunol; 2007 Sep; 179(6):3888-95. PubMed ID: 17785826
[TBL] [Abstract][Full Text] [Related]
14. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.
Kawano T; Cui J; Koezuka Y; Toura I; Kaneko Y; Sato H; Kondo E; Harada M; Koseki H; Nakayama T; Tanaka Y; Taniguchi M
Proc Natl Acad Sci U S A; 1998 May; 95(10):5690-3. PubMed ID: 9576945
[TBL] [Abstract][Full Text] [Related]
15. CD1d-specific NK1.1+ T cells with a transgenic variant TCR.
Sköld M; Faizunnessa NN; Wang CR; Cardell S
J Immunol; 2000 Jul; 165(1):168-74. PubMed ID: 10861049
[TBL] [Abstract][Full Text] [Related]
16. A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage.
Pellicci DG; Hammond KJ; Uldrich AP; Baxter AG; Smyth MJ; Godfrey DI
J Exp Med; 2002 Apr; 195(7):835-44. PubMed ID: 11927628
[TBL] [Abstract][Full Text] [Related]
17. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers.
Benlagha K; Weiss A; Beavis A; Teyton L; Bendelac A
J Exp Med; 2000 Jun; 191(11):1895-903. PubMed ID: 10839805
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms imposing the Vbeta bias of Valpha14 natural killer T cells and consequences for microbial glycolipid recognition.
Wei DG; Curran SA; Savage PB; Teyton L; Bendelac A
J Exp Med; 2006 May; 203(5):1197-207. PubMed ID: 16651387
[TBL] [Abstract][Full Text] [Related]
19. Multiple constraints at the level of TCRalpha rearrangement impact Valpha14i NKT cell development.
Hager E; Hawwari A; Matsuda JL; Krangel MS; Gapin L
J Immunol; 2007 Aug; 179(4):2228-34. PubMed ID: 17675483
[TBL] [Abstract][Full Text] [Related]
20. Cutting edge: influence of the TCR V beta domain on the avidity of CD1d:alpha-galactosylceramide binding by invariant V alpha 14 NKT cells.
Schümann J; Voyle RB; Wei BY; MacDonald HR
J Immunol; 2003 Jun; 170(12):5815-9. PubMed ID: 12794105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
